Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., today announced positive topline results from the Phase 3 AZTOUND trial evaluating pharmacokinetic (PK) exposure, safety and efficacy of an ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...

A simple measurement that can be taken from any routine blood sample is attracting renewed attention as a possible prognostic ...

Allogeneic hematopoietic cell transplantation achieved a 3-year overall survival of 69% in adults aged 18 to 40 years with ...

MRD can reveal residual MDS beyond morphology, but heterogeneous clones and assay limitations complicate interpretation.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A cheap supplement produced an unexpected signal in a trial that had been built to test something else entirely.

It is sold to millions of Americans for energy, focus and healthy aging, and researchers finally put the pill to a real test.

On Tuesday, InnoCare Pharma Limited (9969.HK), a biopharmaceutical company, received approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to ...

Taiho Oncology Announced Positive Phase 3 Trial Results for Azacitidine and Cedazuridine in MDS and CMML / azacitidine, cancer, cedazuridine, chronic ...

A patient can move into a higher-risk category through rising blasts, worsening cytopenias, adverse genetics, or a ...

In the first reported case of the autoinflammatory VEXAS syndrome in South Africa, J Damelin, J Jacobson, C Bam, L Pillay and ...